Clinical Importance of the LDL-C/Apolipoprotein B Ratio for Neointimal Formation after Everolimus-Eluting Stent Implantations

Naotaka Akutsu¹, Koichiro Hori¹, Saki Mizobuchi¹, Akihito Ogaku¹, Yutaka Koyama¹, Hidesato Fujito¹, Riku Arai¹, Yasunari Ebuchi¹, Suguru Migita¹, Tomoyuki Morikawa¹, Takehiro Tamaki¹, Keisuke Kojima¹, Nobuhiro Murata¹, Toshihiko Nishida¹, Daisuke Kitano¹,², Daisuke Fukamachi¹ and Yasuo Okumura¹

¹Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
²Division of Advanced Cardiovascular Imaging, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Aims: Smaller low-density lipoprotein (LDL) particle size has been suggested to result in the development of endothelial dysfunction, atherosclerosis, and in-stent restenosis (ISR); however, little is known regarding the impact of the LDL particle size on the neointima formation leading to ISR after everolimus-eluting stent (EES) implantation.

Methods: In this study, we have included 100 patients to examine the relationship between an LDL-C/apolipoprotein B (Apo B) ≤ 1.2, reportedly representing the LDL particle size, and the neointimal characteristics using optical coherence tomography (OCT) and coronary angioscopy (CAS) during the follow-up coronary angiography (CAG) period (8.8 ± 2.5 months) after EES implantation. We divided them into two groups: LDL-C/Apo B ≤ 1.2 group (low LDL-C/Apo B group, n = 53) and LDL-C/Apo B > 1.2 group (high LDL-C/Apo B group, n = 47).

Results: The low LDL-C/Apo B group had a significantly larger neointimal volume (12.8 ± 5.3 vs. 10.3 ± 4.9 mm³, p = 0.021) and lower incidence of a neointimal homogeneous pattern (71 vs. 89 %), higher incidence of a neointimal heterogeneous pattern (25 vs. 9 %) (p = 0.006) and higher prevalence of macrophage accumulation (9 vs. 2 %) (p = 0.030) as assessed via OCT, and, as per the CAS findings, a higher prevalence of yellow grade ≥ 2 (grade 2; adjusted residual: 2.94, grade 3; adjusted residual: 2.00, p = 0.017) than the high LDL-C/Apo B group.

Conclusions: A low LDL-C/Apo B ratio was found to be strongly associated with neointimal proliferation and neointimal instability evidenced chronically by OCT and CAS. An LDL-C/Apo B ≤ 1.2 will be of aid in terms of identifying high-risk patients after EES implantation.

Key words: Low-Density Lipoprotein Cholesterol (LDL-C)/apolipoprotein B ratio, Neointimal volume, Neointimal grade, Yellow grade, Everolimus-eluting stent, Optical coherence tomography, Coronary angioscopy

1. Introduction

Low-density lipoprotein cholesterol (LDL-C) is a collection of broad lipoproteins with a specific gravity of 1.019 to 1.063 g/mL and has several subfractions with different particle sizes. Among the LDL-C subfractions, LDL-Cs with a small particle size and heavy gravity is defined as small dense LDL-C (sd-LDL-C). The sd-LDL-C has been often associated with atherosclerosis lipoproteins because of its low affinity for the LDL receptors, easy penetration into the vessel walls, long blood half-life, and high oxidizability¹. Numerous reports have suggested a relationship between sd-LDL-C and the onset of cardiovascular diseases (CVDs)²-⁴, but a direct measurement of sd-LDL-C has not been widely used.
in clinical practice in Japan. The LDL-C/apolipoprotein B (Apo B) ratio has been reported to indirectly express the LDL particle size\(^5\). An LDL particle size of \(\leq 25.5\) nm is the cutoff value for the classification between a large buoyant LDL and sd-LDL. This cutoff value is suggested to correspond to an LDL-C/Apo B ratio of \(\leq 1.2\); therefore, it indicates a predominance of sd-LDL particles\(^6\). On the other hand, coronary imaging modalities such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and coronary angiography (CAS) can assess the detailed characteristics of the neointimal tissues at the implanted stent site. Especially, the OCT-derived neointimal characteristics and CAS-derived yellow grade have been identified to be well-known markers for vulnerable plaque or neointimal characteristics using both OCT and CAS during the follow-up CAG period after implantation of third-generation drug-eluting stents (DESs)\(^9\), \(^10\).

2. Aim

We, herein, evaluated the relationship between an LDL-C/Apo B ratio \(\leq 1.2\) (reflecting the predominance of the sd-LDL particles) and the future neointimal characteristics after third-generation everolimus-eluting stent (EES) implantation using OCT and CAS.

3. Methods

3.1 Study Population

The data analyzed in this study were retrospectively obtained from 465 consecutive patients who underwent elective percutaneous coronary intervention (PCI) from April 2016 to March 2019. The inclusion criteria were patients who underwent third-generation EES implantations for stable angina and with stenting site assessed by OCT and CAS during the follow-up CAG and those in whom the LDL-C and apolipoprotein B levels were measured. Among the 465 patients, the following were excluded from the study: 21 who had a history of coronary artery bypass grafting (CABG), 105 who had incomplete imaging studies (in terms of the imaging quality or timing), 39 with missing CAS data, 239 with missing OCT data, and 125 with missing Apo B data. As a result, the remaining 100 patients were included for analysis. We then divided them into two groups according to an LDL-C/Apo B level of 1.2 at the time of PCI: low LDL-C/Apo B \(\leq 1.2\) group \([n=53]\) and high LDL-C/Apo B \(>1.2\) group \([n=47]\). This study was a retrospective observational study; thus, it was carried out via opt-out method on our hospital websites. The study protocol was reviewed and approved by the Ethics Committee of Nihon University Itabashi Hospital.

3.2 Patient Characteristics, Laboratory and Procedural Parameters, and Clinical Outcomes

The patient characteristics at the time of PCI were obtained by reviewing their respective hospital charts. Blood samples were collected after about 10–12 hours of fasting in the early morning on the day of the PCI. The LDL-C serum level was measured using the Friedewald formula\(^11\), and the serum Apo B level and malondialdehyde-modified LDL (MDA-LDL) level, which is a molecular species of oxidized LDL, were measured via turbidimetric latex agglutination assays (SRL).

3.3 Optical Coherence Tomography

OCT was performed during the follow-up CAG in the total study patients. The SJM FD-OCT imaging system (Abbott Medical Japan Co., Ltd. and LightLab Imaging, Inc., USA) and SJM FD-OCT Integrated imaging system (Abbott Medical Japan Co., Ltd., LightLab Imaging, Inc., USA, and St. Jude Medical, Atrial Fibrillation Division, Inc., USA) were used in this present study. The brief OCT method was described elsewhere\(^12\). The image analysis was performed using the SJM FD-OCT Integrated imaging system (Abbott Medical Japan Co., Ltd., LightLab Imaging, Inc., USA, and St. Jude Medical, Atrial Fibrillation Division, Inc, USA). As for the OCT assessment, the lumen and stent areas were traced automatically (Fig. 1A). The neointimal area was defined and calculated as the stent area minus the lumen area\(^13\), whereas the neointimal area \(\times\) the number of slices \(\times\) neointimal area. For a qualitative analysis, the OCT signal patterns of the neointimal tissue were categorized into three patterns based on Gonzalo’s classification\(^13\): homogeneous, heterogeneous, and layered patterns (as shown in Fig. 1B). An assessment of the tissue characteristics was carried out at the in-stent maximal lumen narrowing site, as determined by the agreement of two observers blinded to the clinical and procedural characteristics\(^14\).
Fig. 1. Representative image of the assessment of the intravascular OCT volume (A), OCT signal patterns of the neointimal tissue (B) and an OCT signal pattern of the macrophage (C). Guide-wire artifact. (D) Macrophage accumulation was defined as signal-rich, distinct, or confluent punctate that exceeded the intensity of the background speckle noise. Representative images used to classify the neointimal coverage grade and that of the yellow grade assessed by CAS. The details are shown in the text. CAS, coronary angioscopy; OCT, optical coherence tomography.
We have also examined the accumulation of macrophages. Macrophage accumulation was defined as signal-rich, distinct, or confluent punctate that exceeded the intensity of the background speckle noise (Fig. 1C). At least, one macrophage accumulation was noted every 1 mm from the distal to the proximal stent edge and was defined as the presence of macrophage accumulation.

3.4 Coronary Angioscopy

During the follow-up CAG, all patients underwent CAS to evaluate the yellow grade (maximum grade) and neointimal coverage grade (minimum grade) at the proximal, mid, and distal sites of each stent. CAS was performed using a VISIBLE fiber imaging catheter (FiberTech Co. Ltd., Japan) and i-Light endoscope system (iHeart Medical Co. Ltd., Japan). The outer section of a 4F probing catheter (Medikit, Japan) was used to guide for the insertion of the optical fiber into the coronary artery. While the angioscopic observations were carried out, blood was removed from the view by injecting 10% dextran through the probing catheter as previously reported\(^\text{15, 16}\). The angioscopy images were recorded on a digital recorder.

The neointimal grade on the stent struts and yellow grade of the plaque, which reportedly indicate plaque vulnerability, were assessed by classifying them into four grades as previously described\(^\text{19}\). The neointimal grades were as follows: grade 0, complete exposure of the stent struts; grade 1, dull light reflection from the stent struts; grade 2, no light reflection from the stent struts with slightly visible struts; and grade 3, complete coverage (Fig. 1D). The yellow grade was classified as either of the following: grade 0, white; grade 1, light yellow; grade 2, yellow; or grade 3, bright yellow (Fig. 1E)\(^\text{17}\). The CAS evaluations were made by two independent coronary intervention specialists and angioscopy by those blinded to the patients’ clinical status. In case of disagreement, the plaque color was reevaluated. If the reevaluations remained discordant, the disagreement was resolved through discussion until a consensus was reached.

4. Results

4.1 Baseline Patient, Lipid Profile, and Procedural Characteristics

The patients and lesion characteristics at the time of PCI per study group in the total patients are presented in Table 1. In brief, no differences were noted in terms of age, height, or body weight, the prevalence of male sex, medication use, hemoglobin A1c level, and the high-sensitivity CRP levels. The proportion of hypertension cases in the “Low LDL-C/Apo B” group was higher than that in the “High LDL-C/Apo B” group (70 vs. 45 %, \(p=0.011\)). No definitive difference was noted in the stent sites between the two groups. The PCI procedural characteristics between the “Low LDL-C/Apo B” and “High LDL-C/Apo B” groups are shown in Table 1. The stent profiles and the predilatation and postdilatation balloon profiles were observed to not significantly differ between the two groups.

4.2 Findings of Intracoronary Imaging in the Follow-Up CAG in the “Low LDL-C/Apo B” and “High LDL-C/Apo B” Groups

The follow-up CAG was performed at 8.9 ± 2.8 months after the initial PCI for the “Low LDL-C/Apo B” group and 8.6 ± 2.1 months for the “High LDL-C/Apo B” group (\(p=0.57\)). A representative example of the OCT-derived neointimal volume obtained during the follow-up CAG between the two groups is shown in Fig. 2A. Among those patients, the OCT-derived neointimal volume was significantly larger (12.8 ± 5.3 vs. 10.3 ± 4.9 mm\(^3\), \(p=0.021\)), and lumen volume in the “Low LDL-C/Apo B” group was smaller than that.
Table 1. Patient characteristics at the time of PCI per study group

|                                | Low LDL-C/Apo B group (n = 53) | High LDL-C/Apo B group (n = 47) | p value* |
|--------------------------------|--------------------------------|---------------------------------|----------|
| Age (years)                    | 65.6 ± 11.8                    | 64.6 ± 13.8                     | 0.71     |
| Male sex                       | 45 (85)                        | 39 (83)                         | 0.79     |
| Height (cm)                    | 164.7 ± 9.4                    | 163.8 ± 9.3                     | 0.66     |
| Weight (kg)                    | 66.7 ± 14.4                    | 65.6 ± 14.4                     | 0.70     |
| Body mass index (kg/m²)        | 24.4 ± 3.6                     | 24.3 ± 3.4                      | 0.85     |
| Medication use                 |                                |                                 |          |
| DAPT                           | 53 (100)                       | 47 (100)                        | 0.99     |
| ACE-I/ARB                      | 38 (72)                        | 37 (79)                         | 0.42     |
| β-blockers                     | 25 (47)                        | 28 (60)                         | 0.21     |
| Statins                        | 50 (94)                        | 43 (91)                         | 0.58     |
| Maximum dose of any statin     | 12 (24)                        | 6 (14)                          | 0.22     |
| Comorbidities                  |                                |                                 |          |
| Hypertension                   | 37 (70)                        | 21 (45)                         | 0.011    |
| Diabetes                       | 16 (30)                        | 9 (19)                          | 0.20     |
| Hemodialysis                   | 2 (4)                          | 2 (4)                           | 0.90     |
| Laboratory examination         |                                |                                 |          |
| Hemoglobin A1c (NGSP) (%)      | 6.3 ± 0.8                      | 6.4 ± 0.9                       | 0.76     |
| High-sense CRP (mg/dL)         | 0.132 (0.068-0.679)            | 0.103 (0.027-0.273)             | 0.11     |
| cGFR (mL/min/1.73mm²)          | 61.8 ± 24.4                    | 71.9 ± 28.7                     | 0.19     |
| Coronary features              |                                |                                 |          |
| Stented vessels                |                                |                                 |          |
| LMT                            | 0 (0)                          | 0 (0)                           | >0.99    |
| LAD                            | 34 (64)                        | 32 (68)                         | 0.34     |
| LCX                            | 9 (17)                         | 6 (13)                          | 0.56     |
| RCA                            | 10 (19)                        | 9 (19)                          | 0.97     |
| Stent profiles                 |                                |                                 |          |
| Diameter (mm)                  | 3.2 ± 0.5                      | 3.0 ± 0.5                       | 0.20     |
| Length (mm)                    | 25.6 ± 7.2                     | 27.9 ± 8.3                      | 0.14     |
| Predilatation (%)              | 45 (82)                        | 42 (88)                         | 0.51     |
| Diameter (mm)                  | 2.3 ± 0.5                      | 2.3 ± 0.3                       | 0.41     |
| Length (mm)                    | 13.3 ± 1.7                     | 13.6 ± 1.6                      | 0.43     |
| Scoring balloon (n)            | 12 (27)                        | 8 (19)                          | 0.40     |
| Postdilatation (%)             | 42 (79)                        | 36 (77)                         | 0.75     |
| Diameter (mm)                  | 3.2 ± 0.5                      | 3.1 ± 0.6                       | 0.22     |
| Length (mm)                    | 12.1 ± 2.9                     | 11.6 ± 1.6                      | 0.35     |

Values are the mean ± SD, median (interquartile ranges), or n (%). Abbreviations: ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker; DAPT, dual antiplatelet therapy; cGFR, estimated-glomerular filtration rate; high-sense CRP, high-sense C-reactive protein; NGSP, national glycohemoglobin standardization program; LMT, left main trunk; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery *by a Student t test, Mann-Whitney U test, chi-square test, or Fisher exact test as appropriate. **

in the “High LDL-C/Apo B” group (47.9 ± 21.0 vs. 56.9 ± 22.9 mm², p = 0.044) (Fig. 2B). With regard to the neointimal properties, the homogeneous pattern in the “Low LDL-C/Apo B” group had a significantly lower proportion than predicted, as compared to the “High LDL-C/Apo B” group (71% vs. 89%, adjusted residual: −2.01). Furthermore, the heterogeneous pattern in the “Low LDL-C/Apo B” group had a significantly higher proportion than predicted as compared to the “High LDL-C/Apo B” group (25% vs. 9%, adjusted residual: 3.88) (chi-square test: p = 0.006) (Fig. 2C). Regarding the macrophage accumulation, the “Low LDL-C/Apo B” group had a significantly higher proportion than predicted as compared to the “High LDL-C/Apo B” group (9% vs 5%/53) vs. 2% vs 1%/47, chi-square test: p = 0.030, adjusted residual: 6.54).

The CAS assessment of the neointimal grade
revealed that a neointimal grade ≥ 2 in the “Low LDL-C/Apo B” group has exhibited significantly higher proportions than predicted as compared with the “High LDL-C/Apo B” group (54 % vs. 24 %, chi-square test: \( p < 0.001 \)) (adjusted residual; grade 2: 4.03, grade 3: 2.74) (Fig. 2D). Higher proportions were also observed than predicted of yellow grade ≥ 2 in the “Low LDL-C/Apo B” group than in the “High LDL-C/Apo B” group (32 % vs. 15 %, chi-square test: \( p = 0.017 \)) (adjusted residual; grade 2: 2.94, grade...
4.3 Contributive Factors for the OCT-Derived Neointimal Volume and CAS-Derived Neointimal and Yellow Grades

There are already a number of reported lipid parameters that are possibly associated with sd-LDL-C (TG, MDA-LDL, non-HDL, Apo B, LDL-C/HDL-C ratio, and non-HDL-C/HDL-C ratio); thus, we evaluated the contribution of each lipid parameter to the neointimal volume, neointimal grade, and yellow grade using a single regression analysis (Supplemental Table 1). Among each lipid parameter, the LDL-C/Apo B ratio was noted to have the highest proportion of the contribution to the neointimal volume ($R^2$: 0.05, $p=0.021$), neointimal grade ($R^2$: 0.10, $p=0.001$), and yellow grade ($R^2$: 0.09, $p=0.003$).

Table 2 shows the multiple regression analysis evaluating the factors of the neointimal volume and neointimal grade and yellow grade. In the multivariate analysis, an LDL-C/Apo B ratio $\leq 1.2$ remained an independent factor for the neointimal volume (odds ratio [OR]: 4.62 [95% confidence interval (CI) 1.53–14.0], $p=0.006$) and neointimal grade (OR: 2.98 [95% CI 1.58–8.96], $p=0.013$). In terms of the yellow grade, the LDL-C/Apo B ratio (OR: 3.57 [95% CI, 1.71–12.6], $p=0.024$) remained an independent factor for the yellow grade.

4.4 Lipid Profile Changes under Statin Treatments from the Initial PCI to the Follow-Up CAG and its Association to the OCT-Derived Neointimal Volume and CAS-Derived Neointimal and Yellow Grades

In the “Low LDL-C/Apo B” group at the time of PCI ($n=53$), majority of the cases (36 [67.9%]) maintained an LDL-C/Apo B ratio of $\leq 1.2$ during the follow-up (categorized as the L-to-L group), while the remaining 17 (32.1%) had an increased LDL-C/Apo B ratio of $>1.2$ during the follow-up (L-to-H group). Among the 47 cases in the “High LDL-C/Apo B” group, 24 (51.1%) had an LDL-C/Apo B ratio of $>1.2$ during the follow-up (H-to-H group), while the remaining 23 (48.9%) had a decreased LDL-C/Apo B ratio of $\leq 1.2$ during the follow-up (H-to-L group). No differences were noted in terms of age, body mass index, comorbidities, and medication use including statins; however, the L-to-H group had the highest rate of maximum dose of any statin (29%, $p=0.010$, adjusted residual: 2.99) among the four groups (Table 3). The stent profiles, that is, the predilatation and postdilatation balloon profiles, did not significantly differ among the four groups. The lipid profile changes under the statin treatment from the time of PCI to the follow-up CAG period are presented in Table 4. A greater decrease in TG from the time of PCI to the follow-up CAG was observed in the L-to-H and H-to-H groups than in the L-to-L and H-to-L groups ($p<0.001$). Also, a greater reduction in the Apo B as compared to the LDL-C was observed in the L-to-H and H-to-H groups compared to the other two groups (despite no statistical difference ($p=0.28$)). The OCT-derived stent, lumen, and neointimal volumes and the CAS-derived neointimal and yellow grades obtained during the follow-up CAG among the four groups are shown in Fig. 3. The neointimal volume was significantly larger in the L-to-L group and tended to be larger in the L-to-H and H-to-L groups than that in the H-to-H group.

Table 2. Factors of the neointimal volume on OCT and neointimal grade and yellow grade on CAS adjusted by the significant variables

| Variables | Neointimal volume | Neointimal grade | Yellow grade |
|-----------|------------------|-----------------|--------------|
|           | OR (95% CI)      | $p$ value       | OR (95% CI)  | $p$ value |
| Age       | 0.99 (0.96–1.03) | 0.77            | 1.02 (0.98–1.06) | 0.26 |
| Sex       | 0.63 (0.17–2.30) | 0.49            | 0.82 (0.23–3.01) | 0.77 |
| DM        | 1.62 (0.56–4.69) | 0.38            | 1.48 (0.50–4.32) | 0.49 |
| LDL-C     | 1.01 (0.99–1.03) | 0.24            | 0.99 (0.97–1.01) | 0.23 |
| HDL-C     | 0.99 (0.96–1.04) | 0.85            | 1.02 (0.97–1.06) | 0.50 |
| Log-transformed TG | 3.31 (0.41–7.96) | 0.20 | 1.26 (0.09–17.8) | 0.86 |
| Log-transformed MDA-LDL | 16.3 (0.59–452) | 0.09 | 7.21 (0.24–217) | 0.26 |
| Log-transformed Apo B | 1.06 (0.04–2.98) | 0.42 | 6.61 (0.06–212) | 0.29 |
| LDL-C/Apo B $\leq 1.2$ (vs. $>1.2$) | 4.62 (1.53–14.0) | 0.006 | 2.98 (1.58–8.96) | 0.013 |
| Log-transformed hs-CRP | 2.12 (0.96–4.68) | 0.06 | 2.07 (0.85–5.00) | 0.11 |

Abbreviations: Apo B, apolipoprotein B; CAS, coronary angiography; CI, confidence interval; HDL-C, high-density lipoprotein-cholesterol; hs-CRP, high-sensitivity C-relative protein; LDL-C, low-density lipoprotein-cholesterol; MDA-LDL, Malondialdehyde-modified low-density lipoprotein; NA, not applicable; OCT, optical coherence tomography; OR, odds ratio; TG, triglyceride.
The H-to-H group was determined to have a significantly lower proportion than predicted as compared to the other three groups (p < 0.038, adjusted residual: −10.36). The neointimal grade was significantly higher in the L-to-L and H-to-L groups than that of the L-to-H and the H-to-H groups (grade 1.66 ± 0.56 and 1.47 ± 0.58 vs. 1.15 ± 0.45, and 1.03 ± 0.15, p < 0.001). The yellow grade was significantly higher in the L-to-L group and (13.1 ± 5.5, 10.7 ± 3.1, and 11.8 ± 5.7 vs. 8.9 ± 3.5 mm³, p = 0.009). Also, the lumen volume in the L-to-L group was significantly smaller than that in the H-to-H group (44.6 ± 18.0 vs. 60.3 ± 25.0 mm³, p = 0.045 by Bonferroni post-hoc adjustment). With regard to the accumulation of macrophages, macrophages were found in three cases (8%) in the L-to-L group, two cases (9%) in the H-to-L group, one case (6%) in the L-to-H group, and zero cases (0%) in the H-to-H group. The H-to-H group was determined to have a significantly lower proportion than predicted as compared to the other three groups (p < 0.038, adjusted residual: −10.36). The neointimal grade was significantly higher in the L-to-L and H-to-L groups than that of the L-to-H and the H-to-H groups (grade 1.66 ± 0.56 and 1.47 ± 0.58 vs. 1.15 ± 0.45, and 1.03 ± 0.15, p < 0.001). The yellow grade was significantly higher in the L-to-L group and

Table 3. Patients characteristics at the time of PCI among the groups of the 4 types of changes in the LDL-C/Apo B ratio

|                      | Low-Low group | Low-High group | High-Low group | High-High group | p value |
|----------------------|--------------|---------------|---------------|----------------|---------|
| Age (years)          | 68.1 ± 10.4  | 60.0 ± 12.5   | 67.5 ± 12.4   | 61.8 ± 14.4    | 0.06    |
| Male sex             | 31 (82)      | 14 (82)       | 19 (83)       | 20 (83)        | 0.50    |
| Height (cm)          | 165.0 ± 9.8  | 164.7 ± 8.7   | 163.9 ± 9.8   | 163.8 ± 8.8    | 0.95    |
| Weight (kg)          | 65.1 ± 13.7  | 70.8 ± 14.9   | 67.2 ± 13.7   | 64.1 ± 14.9    | 0.47    |
| Body mass index (kg/m²) | 23.7 ± 3.5  | 25.9 ± 3.3    | 24.9 ± 4.2    | 23.6 ± 4.0     | 0.18    |
| Medication use       |              |               |               |                |         |
| DAPT                 | 36 (100)     | 17 (100)      | 23 (100)      | 24 (100)       | 0.99    |
| ACE-I/ARB            | 25 (69)      | 13 (76)       | 19 (79)       | 17 (71)        | 0.69    |
| β-blockers           | 16 (44)      | 11 (65)       | 15 (65)       | 13 (54)        | 0.36    |
| Statins              | 34 (94)      | 16 (94)       | 22 (96)       | 23 (96)        | 0.99    |
| Maximum dose of any statin | 7 (19) | 5 (29)        | 3 (13)        | 3 (13)         | 0.010   |
| Comorbidities        |              |               |               |                |         |
| Hypertension         | 22 (61)      | 13 (76)       | 9 (39)        | 12 (50)        | 0.09    |
| Diabetes             | 9 (25)       | 2 (12)        | 6 (26)        | 8 (33)         | 0.48    |
| Hemodialysis         | 2 (6)        | 0 (0)         | 0 (0)         | 2 (8)          | 0.38    |
| Laboratory examination |            |               |               |                |         |
| Hemoglobin A1c (NGSP) (%) | 6.2 ± 0.8  | 6.1 ± 0.6     | 6.2 ± 0.7     | 6.3 ± 0.7      | 0.83    |
| eGFR(mL/min/1.73mm²)  | 60.3 ± 18.8  | 63.7 ± 15.3   | 66.6 ± 11.9   | 72.4 ± 28.1    | 0.15    |
| High-sense CRP (mg/dL) | 0.153 (0.093-0.227) | 0.095 (0.019-0.636) | 0.151 (0.027-0.327) | 0.099 (0.024-0.381) | 0.54    |
| Coronary features    |              |               |               |                |         |
| Stented vessels      |              |               |               |                |         |
| LMT                  | 0 (0)        | 0 (0)         | 0 (0)         | 0 (0)          | 0.99    |
| LAD                  | 22 (61)      | 6 (35)        | 17 (74)       | 18 (75)        | 0.040   |
| LCX                  | 6 (17)       | 3 (18)        | 2 (9)         | 1 (4)          | 0.41    |
| RCA                  | 8 (22)       | 8 (47)        | 4 (17)        | 5 (21)         | 0.14    |
| Stent profiles       |              |               |               |                |         |
| Diameter (mm)        | 3.1 ± 0.4    | 3.3 ± 0.5     | 3.1 ± 0.4     | 3.0 ± 0.5      | 0.13    |
| Length (mm)          | 25.7 ± 7.5   | 25.4 ± 6.7    | 28.5 ± 7.4    | 27.3 ± 9.0     | 0.49    |
| Predilatation (%)    | 30 (83)      | 15 (88)       | 21 (91)       | 21 (88)        | 0.84    |
| Diameter (mm)        | 2.3 ± 0.4    | 2.4 ± 0.5     | 2.2 ± 0.3     | 2.3 ± 0.3      | 0.67    |
| Length (mm)          | 13.5 ± 1.6   | 12.9 ± 1.9    | 13.6 ± 1.7    | 13.6 ± 1.5     | 0.66    |
| Scoring balloon (n)  | 6 (20)       | 2 (13)        | 2 (10)        | 3 (14)         | 0.67    |
| Postdilatation (%)   | 31 (86)      | 11 (65)       | 16 (70)       | 21 (88)        | 0.14    |
| Diameter (mm)        | 2.3 ± 0.4    | 2.4 ± 0.5     | 2.2 ± 0.3     | 2.3 ± 0.3      | 0.18    |
| Length (mm)          | 13.5 ± 1.6   | 12.9 ± 1.9    | 13.6 ± 1.7    | 13.6 ± 1.5     | 0.32    |

Values are the mean ± SD, median (interquartile ranges), or n (%). Abbreviations: ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker; DAPT, dual antiplatelet therapy; eGFR, estimated-glomerular filtration rate; high-sense CRP, high-sense C-reactive protein; NGSP, national glycohemoglobin standardization program; LMT, left main trunk; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery * by a Student-t test, Mann-Whitney U test, chi-square test, Fisher exact test, an ANOVA, and Kruskal-Walls test as appropriate.
significant negative correlation with triglyceride (TG) concentration (Spearman’s rank correlation coefficient; \( r = -0.28, p = 0.004 \)). Further, the LDL-C/Apo B ratio also had a significant negative correlation with TG/HDL-C, which predicted the quantity of the sd-LDL-C (\( r = -0.40, p < 0.001 \) (Fig. 4)).

### 4.5 The Correlation between LDL-C/Apo B and Other Lipid Profiles

As per our findings, the LDL-C/Apo B ratio during the follow-up period was determined to have a significant negative correlation with triglyceride (TG) concentration (Spearman’s rank correlation coefficient; \( r = -0.28, p = 0.004 \)). Further, the LDL-C/Apo B ratio also had a significant negative correlation with TG/HDL-C, which predicted the quantity of the sd-LDL-C (\( r = -0.40, p < 0.001 \) (Fig. 4)).

### Table 4. Lipid profile changes under statin treatments from the time of PCI to the follow-up CAG period among the groups of the 4 types of changes in the LDL-C/Apo B ratio

|                          | Low-Low group (n = 36) | Low-High group (n = 17) | High-Low group (n = 23) | High-High group (n = 24) | \( p \) value |
|--------------------------|------------------------|-------------------------|-------------------------|--------------------------|--------------|
| Total cholesterol (mg/dL)|                        |                         |                         |                          |              |
| Time of PCI              | 157.0 (140.0-184.0)     | 148.0 (140.0-179.5)     | 185.0 (157.0-210.0)     | 188.0 (158.5-234.0)      | 0.002        |
| Follow-up CAG            | 155.0 (140.8-167.3)     | 157.0 (139.0-170.5)     | 140.0 (129.0-156.0)     | 168.5 (144.3-185.0)      | 0.014        |
| \( \Delta \) (%)         | -1.2                   | +6.2                    | -24.9                   | -10.4                    | <0.001       |
| LDL-C (mg/dL)            |                        |                         |                         |                          |              |
| Time of PCI              | 88.7 ± 22.8            | 84.5 ± 26.6             | 118.0 ± 32.6            | 118.8 ± 38.8             | <0.001       |
| Follow-up CAG            | 79.2 ± 18.8            | 89.2 ± 16.6             | 72.5 ± 18.9             | 94.3 ± 23.5              | 0.001        |
| \( \Delta \) (%)         | -10.8                  | +5.5                    | -38.5                   | -20.6                    | <0.001       |
| HDL-C (mg/dL)            |                        |                         |                         |                          |              |
| Time of PCI              | 44.1 ± 12.1            | 44.1 ± 13.2             | 44.0 ± 9.0              | 49.1 ± 14.6              | 0.41         |
| Follow-up CAG            | 45.9 ± 14.1            | 47.8 ± 10.2             | 42.7 ± 8.4              | 53.9 ± 12.0              | 0.014        |
| \( \Delta \) (%)         | +4.1                   | +8.4                    | -2.9                    | +9.8                     | 0.05         |
| Triglyceride (mg/dL)     |                        |                         |                         |                          |              |
| Time of PCI              | 132.5 (90.0-185.0)      | 144.0 (116.5-189.5)     | 106.0 (76.0-124.0)      | 120.5 (82.8-164.8)       | 0.11         |
| Follow-up CAG            | 145.5 (114.3-203.3)     | 101.0 (81.0-151.3)      | 96.0 (79.0-124.0)       | 84.0 (68.0-101.5)        | <0.001       |
| \( \Delta \) (%)         | +9.8                   | -29.9                   | -9.4                    | -30.2                    | <0.001       |
| Non-HDL-C (mg/dL)        |                        |                         |                         |                          |              |
| Time of PCI              | 126.0 (106.5-139.8)     | 103.0 (93.0-137.8)      | 151.0 (111.0-168.0)     | 141.5 (102.5-171.8)      | 0.009        |
| Follow-up CAG            | 111.0 (96.0-128.5)      | 108.0 (89.0-122.3)      | 101.0 (84.0-118.0)      | 119.0 (93.3-133.0)       | 0.35         |
| \( \Delta \) (%)         | -11.9                  | +4.8                    | -33.1                   | -15.9                    | <0.001       |
| Apo B (mg/dL)            |                        |                         |                         |                          |              |
| Time of PCI              | 98.0 (71.0-105.0)       | 92.0 (72.0-110.5)       | 79.0 (64.0-93.5)        | 93.0 (80.0-109.0)        | 0.13         |
| Follow-up CAG            | 79.0 (64.0-94.8)        | 67.0 (60.5-73.0)        | 74.0 (56.0-87.0)        | 71.0 (54.0-88.8)         | 0.15         |
| \( \Delta \) (%)         | -13.2                  | -24.4                   | -5.2                    | -23.7                    | 0.28         |
| MDA-LDL (U/L)            |                        |                         |                         |                          |              |
| Time of PCI              | 111.0 (81.5-145.0)      | 95.0 (76.0-146.3)       | 118.0 (91.0-140.0)      | 126.0 (79.0-176.3)       | 0.73         |
| Follow-up CAG            | 120.0 (76.0-120.0)      | 71.5 (58.0-96.0)        | 75.5 (59.0-90.0)        | 84.0 (70.0-94.0)         | 0.038        |
| \( \Delta \) (%)         | +10.0                  | -24.7                   | -36.0                   | -33.3                    | 0.025        |
| LDL-C/ApoB ratio         |                        |                         |                         |                          |              |
| Time of PCI              | 1.01 (0.75-1.11)        | 0.97 (0.83-1.11)        | 1.38 (1.33-1.49)        | 1.40 (1.36-1.50)         | <0.001       |
| Follow-up CAG            | 1.02 (0.97-1.10)        | 1.30 (1.25-1.45)        | 1.04 (0.90-1.11)        | 1.30 (1.25-1.37)         | <0.001       |
| \( \Delta \) (%)         | +0.1                   | +34.0                   | -24.6                   | -7.1                     | <0.001       |
| LDL-C/HDL-C ratio        |                        |                         |                         |                          |              |
| Time of PCI              | 2.11 (1.71-2.33)        | 1.69 (1.44-2.32)        | 3.11 (2.07-3.41)        | 2.40 (1.78-3.24)         | 0.029        |
| Follow-up CAG            | 1.79 (1.40-2.13)        | 1.84 (1.41-2.46)        | 1.84 (1.21-2.21)        | 1.88 (1.36-2.31)         | 0.89         |
| \( \Delta \) (%)         | -15.1                  | +8.8                    | -40.8                   | -21.6                    | 0.001        |

Values are the mean ± SD median (interquartile ranges), or \( n \) (%). Abbreviations: Apo B, apolipoprotein B; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; MDA-LDL, malondialdehyde-modified low-density lipoprotein-cholesterol; \( \Delta \), rate of change from at the time of PCI to the follow-up CAG; * an ANOVA and Kruskal-Wallis test as appropriate.
**Fig. 3.** OCT and CAS imaging findings between the 4 LDL/Apo B categorical groups according to the change in the LDL-C/Apo B ratio from the time of PCI to the follow-up CAG period

The L-to-L group indicates the patients in whom the LDL-C/Apo B ratio was ≤ 1.2 at both the time of PCI and follow-up CAG. The L-to-H group indicates the patients in whom the LDL-C/Apo B ratio was ≤ 1.2 at the time of PCI, but >1.2 during the follow-up CAG, the H-to-L group indicates the patients in whom the LDL-C/Apo B ratio was >1.2 at the time of PCI, but ≤ 1.2 during the follow-up CAG, and the H-to-H group indicates the patients in whom the LDL-C/Apo B ratio is >1.2 at both the time of PCI and follow-up CAG. *p<0.05 vs. H-to-H by Bonferroni post-hoc adjustment. †p<0.05 vs. H-to-H and L-to-H by Steel-Dwass post-hoc adjustment. ††p<0.05 vs. H-to-H by Steel-Dwass post-hoc adjustment. The details are shown in the text.

**Fig. 4.** The correlation between the LDL-C/Apo B ratio and triglyceride concentration and triglyceride/HDL-C

Apo B, Apolipoprotein B.

### 5. Discussion

This study has examined the association between the neointimal characteristics and LDL-C/Apo B ratio, which is an indicator for LDL particle size, using OCT and CAS imaging. There were four main findings of this study. First, despite the similar prevalence of male sex, coronary risk factors, and body weight, the “Low LDL-C/Apo B” ratio patients had a smaller rate of change in terms of TG, MDA-LDL, LDL-C, and Apo B concentration levels compared to that in the “High LDL-C/Apo B” ratio patients. Second, via OCT, the neointimal volume was determined to be significantly larger; meanwhile, via CAS, the neointimal properties were found to have lesser homogeneous pattern, greater heterogeneous pattern, higher prevalence of macrophage accumulation, and higher proportion of neointimal and yellow grades in the “Low LDL-C/Apo B” ratio patients than in the “High LDL-C/Apo B” ratio patients. Third, after the multivariate adjustment, the OCT-derived neointimal volume, neointimal grade, and high yellow grade observed via CAS were all independently associated with low LDL-C/Apo B ratio. Fourth, the patients with persistent “Low LDL-C/Apo B” ratio at the time of PCI to the...
follow-up CAG (L-to-L group) had the greater 
neointimal instability and plaque progression.

5.1 The Role of the LDL-C/Apo B Ratio as an 
Indicator for the Predominance of sd-LDL Particles 
on Neointimal Proliferation

The sd-LDL-C has been recognized as a 
substance that strongly promotes endothelial 
dysfunction, atherosclerosis, and ISR; thus, it has been 
considered as a significant factor in the development 
of CVD2-4). There are various pathways to produce 
sd-LDL-C. The most powerful factor that prescribes 
the LDL particle size is the TG concentration19, 20). In 
hypertriglyceridemia, TG-rich large very-low-density 
lipoprotein 1 (VLDL1) is catabolized in a slow blood 
clearance pool. During this catabolism, the TG-rich 
HDL transfers TG from VLDL1, passes the TG to the 
LDL, extracts the cholesterol from the LDL, and 
eventually produces sd-LDL21, 22). In our study, the 
LDL-C/Apo B ratio was the strongest contributor for 
predicting a large neointimal volume, high neointimal 
grade, and yellow grade among those reported lipid 
parameters. This finding has strongly supported the 
clinical significance of the LDL-C/Apo B ratio as an 
indicator for the predominance of sd-LDL particles, 
promoting neointimal hyperplasia and plaque 
progression.

5.2 Effect of the “Low LDL-C/Apo B Ratio” on the 
Neointimal Characteristics Observed by OCT and 
CAS after Third-Generation DES Implantations

We found a heterogeneous neointimal pattern in the “Low LDL-C/Apo B” group more frequently than in the “High LDL-C/Apo B” group. A heterogeneous pattern is often associated with vascular inflammation induced by the stent with smooth cells in a rich extracellular matrix, whereas a layered pattern is correlated with a healed neointimal erosion and rupture and peri-strut neovascularization with smooth muscle cells in a rich extracellular matrix30). Therefore, those non-homogeneous patterns are often identified 
among the ISR lesions associated with DESs31). Normally, neointimal tissue gradually becomes mature 
and homogeneous via early vascular reaction such as 
thrombus formation and acute inflammation around 
the strut after stent implantations. In a previous 
report, the rate of homogeneous pattern rate had 
increased to 7 1% after 6 months after second-
generation DES implantations32). Despite the use of 
third-generation DES implantations with a longer 
follow-up period of 8.8 months, a lower homogeneous 
pattern rate and higher macrophage accumulation rate 
in the “Low LDL-C/Apo B” group than in the “High 
LDL-C/Apo B” group suggested greater immature 
zeointimal tissue.

In our study, the neointimal volume observed by 
OCT was found to be significantly larger, and the 
proportion of the neointimal coverage grade and 
yellow grade observed by CAS was also observed to be 
higher in the “Low LDL-C/Apo B” group than in the 
“High LDL-C/Apo B” group. Further, even after 
adjusting for the age, sex, and cholesterol profiles, the 
zeointimal volume using OCT and neointimal 
and yellow grades using CAS has remained associated 
with low LDL-C/Apo B values.

In previous reports, the yellow grade in the stent 
was considered to decrease due to the stent being 
covered by neointimal proliferation during the chronic 
phase33-35). However, the neointimal hyperplasia is 
clinically problematic because it is strongly related to 
endothelial dysfunction and vascular inflammation, 
leading to early occurrence of ISR36, 37). In a prior 
study regarding the CAS characteristics of second-
generation DESs, a neointimal coverage grade ≥ 2 was
43% and yellow grade ≥ 2 was 26%, respectively \( ^{38} \). A study comparing the CAS findings of the second- vs. third-generation DESs showed a significantly increased neointimal coverage grade but decreased yellow grade in the third-generation DESs \( ^{38} \). The rate of neointimal grade ≥ 2 in the “Low LDL-C/Apo B” group was 54%, which was slightly higher than that in the second-generation DESs reported previously \( ^{38} \), whereas in the “High LDL-C/Apo B” group, that rate was only 24%. In terms of the yellow grade associated with advanced neatherosclerosis \( ^{8} \), the rate of yellow grade ≥ 2 in the “Low LDL-C/Apo B” group was higher (32%) in the third-generation DESs than that in the second-generation DESs \( ^{38} \); however, in the “High LDL-C/Apo B” group, the rate was much lower (only 15%). The increased neointimal coverage and high yellow grade in the “Low LDL/Apo B” patients may be explained by the baseline patient background (promoting atherosclerosis such as aging, a family history, or lifestyle habit) in which the high yellow grade plaque that originally coexisted or delayed vascular healing caused by incomplete or immature endothelization both generated neointimal instability, hyperplasia, and neatherosclerosis. Through those processes, the low LDL-C/Apo B ratio indicating the predominance of sd-LDL particles may have lessened (or outweigh) the favorable effects of the third-generation DESs on the neointimal tissue as compared to the first- or second-generation DESs or BMSs. In fact, in the L-to-L group (the persistence of a “Low LDL-C/Apo B” level from the time of PCI to the follow-up), the statin treatment did not reduce the TG and MDA-LDL levels, resulting in significantly higher TG and MDA-LDL levels than in the other three groups \( (\text{Table 3}) \). This group had the largest neointimal volume, highest grade of neointima and yellow plaque, and highest macrophage accumulation rate on the OCT and CAS. The MDA-LDL level was considered a major form of an oxidized LDL \( ^{39} \); thus, those observations suggested that, in the L-to-L group, the persistent accumulation of TG-rich lipoproteins such as remnant lipoproteins and/or sd-LDL-C was resistive to the standard statin treatment, which may have contributed to the neointimal instability and plaque progression.

5.3 Clinical Implications

This study found an interesting finding regarding the effects of the change in the lipid profile on the neointimal characteristics, i.e., the L-to-L and H-to-L groups had a higher neointimal volume and grade and yellow grade during the follow-up CAG as compared to the L-to-H and H-to-H groups. These results provided suggestive evidence that maintaining and/or increasing the LDL-C/Apo B ratio > 1.2 is essential to suppress excessive neointimal proliferation and reduce the yellow grade and neointimal instability. Therefore, once the patients have an LDL-C/Apo B ratio ≤ 1.2 from the time of PCI to the follow-up period, a more aggressive therapy for hyperlipidemia by using a strong statin plus ezetimibe, fibrates, or proprotein convertase subtilisin/leukin type 9 inhibitor (PCSK9i) injections should be used. On contrary, scintigraphy or coronary computed tomography may stratify high-risk patients from those in whom an LDL-C/Apo B ratio < 1.2 persists during the follow-up.

5.4 Limitations

This study has some limitations. First, this was the retrospective cross-sectional study, and this study only included a small population for analysis; however, it should be noted that spontaneous assessment with OCT and CAS at the time of the stent implantation and follow-up CAG in all patients is clinically difficult considering the medical cost. Second, we have only evaluated stable angina patients after EES implantations in this study. In this cohort, it may be needed to include high-risk patients, as it might not be possible to generalize the results to other stents implanted in acute coronary syndrome patients. Finally, the weakness of this study was that we did not directly measure the sd-LDL-C. For example, there was a concern that the neointimal instability might contribute to a greater LDL-C reduction (as compared to that of the Apo B) with statin therapy rather than an LDL-C/Apo B ≤ 1.2 as with the predominance of sd-LDL particles. This was not a fact because the LDL-C reduction with statins was correlated with reduced neointimal volume, and decreased rates of neointima and yellow plaque (neointimal stability) (supplemental table). Therefore, our data supported the hypothesis that the neointimal instability after PCI may be partially caused by an LDL-C/Apo B ≤ 1.2 as with the predominance of sd-LDL particles.

6. Conclusion

A low ratio of the LDL-C/Apo B, which is known to be a marker for a predominance of smaller LDL particle size, has been strongly associated with neointimal proliferation and neointimal instability, as confirmed via OCT and CAS. Therefore, a ratio of LDL-C/Apo B of ≤ 1.2 will help in identifying high-risk patients after EES implantations in the future.

Acknowledgements

The author thanks Mr. John Martin for his
encouragement and assistance in the preparation of this commentary in English.

Notice of Grant Support
The author had no grant support.

References

1) Lamarche B, Lemieux I, and Després JP: The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab, 1999; 25: 199-211

2) Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, Okamura T, and Miyamoto Y: Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb, 2013; 20: 195-203

3) Shifman D, Louie JZ, Caulfield MP, Nilsson PM, Devlin JJ, and Melander O: LDL subfractions are associated with incident cardiovascular disease in the Malmö Prevention Project Study. Atherosclerosis, 2017; 263: 287-292

4) Hirayama S, and Miida T: Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta, 2012; 414: 215-224

5) Tani S, Saito Y, Anazawa T, Kawamata H, Furuya S, Takahashi H, Iida K, Matsumoto M, Washio T, Kumabe N, Nagao K, and Hirayama A: Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study. Int Heart J, 2011; 52: 343-347

6) Hirano T, Ito Y, and Yoshino G: Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb, 2005; 12: 67-72

7) Kanaeva AM, Potolitsyna NN, and Bojko ER: Usefulness of the LDL/apoB ratio in the overall evaluation of atherogenicity of lipid profile. Arch Physiol Biochem, 2017; 123: 16-22

8) Ohtani T, Ueda Y, Mizote I, Oyabu J, Okada K, Hirayama A, and Kodama K: Number of yellow plaques detected in a coronary artery is associated with future risk of acute coronary syndrome: detection of vulnerable patients by angiography. J Am Coll Cardiol, 2006; 47: 2194-2200

9) Masawa T, Abe S, Toyoda S, Sakuma M, Nasuno T, Kageyama M, Tokura M, Koizumi S, Taguchi I, and Inoue T: Comparison of the performance of zotarolimus-and everolimus-eluting stents by optical coherence tomography and coronary angiography. Heart Vessels, 2016; 31: 1230-1238

10) Miyoshi T, Matsuoka H, Kawakami H, Dai K, Sato T, Watanabe K, and Ishihara M: Assessment of second- and third-generation drug-eluting stents on chronic coronary angiography—Multicenter Study on Intra-Coronary AngioScopy After Stent (MICASA) prospective data analysis. Circ J, 2018; 82: 1830-1835

11) Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tslepis A, Eliaf M, and Tsalas O: Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem, 2000; 33: 549-555

12) Mehanna EA, Attizzani GF, Kyono H, Hake M, and Bezerra HG: Assessment of coronary stent by optical coherence tomography, methodology and definitions. Int J Cardiovasc Imaging, 2011; 27: 259-269

13) Gonzalo N, Serruys PW, Okamura T, van Beusekom HM, Garcia HM, van Soest G, Garcia-Garcia HM, van Soest G, van der Giessen W, and Regar E: Optical coherence tomography patterns of stent restenosis. Am Heart J, 2009; 158: 284-293

14) Tanimoto S, Aoki J, Serruys PW, and Regar E: Paclitaxel-eluting stent restenosis shows three-layer appearance by optical coherence tomography. Eurointervention, 2006; 1: 484

15) Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Nanto S, Takazawa K, and Kodama K: Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J, 2009; 73: 718-725

16) Ueda Y, Asakura M, Yamaguchi O, Hirayama A, Hori M, and Kodama K: The healing process of infarct-related plaques: Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol, 2001; 38: 1916-1922

17) Kodama K, Komatsu S, Ueda Y, Takayama T, Yajima J, Nanto S, Matsuoka H, Saito S, and Hirayama A: Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound—the TOGETHER trial. Circ J, 2010; 74: 1922-1928

18) Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant, 2013; 48: 452-458

19) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Atherosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333

20) Hirano T, Ito K, Sakai S, Kashiwazaki K, Adachi M, and Yoshino G: High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis, 1998; 141: 77-85

21) Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, and Shepherd J: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis, 1994; 106: 241-253

22) Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, and Seidel D: Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res, 2000; 41: 305-318

23) Ross R: Atherosclerosis—an inflammatory disease. N

Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: February 2, 2021 Published online: March 21, 2021
14

Engl J Med, 1999; 340: 115-126
24) Osterud B, and Bjorklid E: Role of monocytes in atherogenesis. Physiol Rev, 2003; 83: 1069-1112
25) Frab A, Weber DK, Kolodgie FD, Burke AP, and Virmani R: Morphological predictors of restenosis after coronary stenting in humans. Circulation, 2002; 105: 2974-2980
26) Weckbach LT, Preissner KT, and Deindl E: The Role of Midkine in Arteriogenesis, Involving Mechanosensing, Endothelial Cell Proliferation, and Vasodilation. Int J Mol Sci, 2018; 29: pii: E2559. doi: 10.3390
27) Narita H, Chen S, Komori K, and Kadomatsu K: Midkine is expressed by infiltrating macrophages in in-stent restenosis in hypercholesterolemic rabbits. J Vasc Surg, 2008; 47: 1322-1329
28) Park SJ, Kang SJ, Virmani R, Nakano M, and Ueda Y: In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol, 2012; 59: 2051-2057
29) RI King, CM Florkowski, J Yeo, TA Walmsley, BI Shand, RS Scott, and PM George: What is the best predictor of the atherogenic LDL subclass phenotype ‘pattern B’ in patients with type 2 diabetes mellitus? Ann Clin Biochem, 2011; 48: 166-169
30) Lee SY, Hong MK, and Jang Y: Formation and transformation of neointima after drug-eluting stent implantation: Insights from optical coherence tomographic studies. Korean Circ J, 2017; 47: 823-832
31) Habara M, Terashima M, Nasu K, Kaneda H, Yokota D, Ito T, Kurita T, Teramoto T, Kimura M, Kinoshita Y, Tsuchikane E, Asakura Y, and Suzuki T: Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study. Eur Heart J Cardiovasc Imaging, 2013; 14: 276-284
32) Legutko J, Gil RJ, Buszman PE, Kaluza GL, Mintz GS, Roleder, Krol M, Wojdyla R, Pawłowski T, Brzeziński M, Kondys M, Skwara B, Jakala J, Zasadz W, Partyka L, and Dudek D: An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv, 2018; 92: 302-309
33) Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K: Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J, 2006; 27: 2189-2195
34) Sakai S, Mizuno K, Yokoyama S, Tanabe T, Shinada T, Seimiya K, Takano M, Ohba T, Tomimura M, Uemura R, and Imaizumi T: Morphologic changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. J Am Coll Cardiol, 2003; 42: 1558-1565
35) Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K: Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am Heart J, 2006; 152: 1168-1174
36) Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE: Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analysis. Circulation, 1998; 98: 224-233
37) Schwartz RS: Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol, 1998; 81: 14E-17E
38) Okuno S, Ishihara T, Iida O, Asai M, Masuda M, Okamoto S, Nanto K, Kanda T, Tsujiura T, Matsuda Y, Takahara M, Uematsu M, and Mano T: Association of subclinical intrastent thrombus detected 9 months after implantation of 2nd-generation drug-eluting stent with future major adverse cardiac events–A coronary angioscopic study. Circ J, 2018; 82: 2299-2304
39) Yokoi M, Ito T, Fujita H, Sugiyara T, Seo Y, and Ohre N: Increased Serum Malondialdehyde-modified low-density lipoprotein and coronary angiographic progression after drug-eluting stent implantation in patients with stable angina. Circ J, 2020; 84: 1837-1845
**Supplemental Table 1. Contribution of each lipid parameter to the neointimal volume, neointimal grade, and yellow grade**

|                     | Neointimal volume |                | Neointimal grade |                | Yellow grade |                |
|---------------------|-------------------|----------------|------------------|----------------|--------------|----------------|
|                     | Correlation       | Contribution   | Coefficient      | $p$ value      | Correlation   | Contribution   | Coefficient      | $p$ value | Correlation   | Contribution   | Coefficient      | $p$ value |
|                     | coefficient $(R)$ | $(R^2)$        | $(R)$            | $p$ value      | coefficient $(R)$ | $(R^2)$        | $(R)$            | $p$ value | coefficient $(R)$ | $(R^2)$        | $(R)$            | $p$ value |
| Total cholesterol   | -0.20             | 0.04           | 0.044            | -0.29          | 0.08          | 0.003          | -0.21             | 0.04      | 0.037          |
| ΔTotal cholesterol  | -0.04             | $< 0.01$       | 0.68             | -0.18          | 0.03          | 0.029          | -0.15             | 0.02      | 0.14          |
| LDL-C               | 0.11              | 0.01           | 0.26             | 0.19           | 0.03          | 0.07           | 0.24              | 0.05      | 0.018          |
| Δ LDL-C             | -0.19             | 0.03           | 0.07             | -0.29          | 0.08          | 0.002          | -0.27             | 0.08      | 0.003          |
| HDL-C               | -0.18             | 0.03           | 0.08             | -0.09          | 0.01          | 0.34           | -0.01             | $< 0.01$ | 0.95          |
| Δ HDL-C             | 0.20              | 0.04           | 0.044            | 0.17           | 0.03          | -0.10          | $< 0.01$         | 0.01      | 0.98          |
| Triglyceride        | 0.13              | 0.02           | 0.18             | -0.07          | $< 0.01$      | 0.47           | $< 0.01$         | 0.01      | 0.88          |
| Δ Triglyceride      | 0.02              | $< 0.01$       | 0.83             | -0.31          | 0.09          | 0.002          | $< 0.01$         | 0.05      | 0.59          |
| Apolipoprotein B    | 0.12              | 0.02           | 0.22             | 0.10           | 0.01          | 0.30           | 0.02              | $< 0.01$ | 0.87          |
| Δ Apolipoprotein B  | 0.04              | $< 0.01$       | 0.69             | -0.04          | $< 0.01$      | 0.71           | -0.08             | 0.01      | 0.43          |
| MDA-LDL             | 0.09              | 0.01           | 0.40             | 0.09           | 0.01          | 0.39           | 0.03              | $< 0.01$ | 0.74          |
| Δ MDA-LDL           | -0.06             | $< 0.01$       | 0.56             | -0.21          | 0.04          | 0.036          | -0.25             | 0.06      | 0.011          |
| Non-HDL-C           | -0.16             | 0.02           | 0.14             | 0.09           | 0.01          | 0.38           | 0.18              | 0.03      | 0.08          |
| Δ Non-HDL-C         | -0.17             | 0.03           | 0.07             | -0.26          | 0.06          | 0.008          | -0.15             | 0.02      | 0.15          |
| LDL-C/Apo B ratio   | -0.23             | 0.05           | 0.021            | -0.32          | 0.10          | 0.001          | -0.30             | 0.09      | 0.003          |
| Δ LDL-C/Apo B ratio | 0.22              | 0.05           | 0.022            | 0.21           | 0.04          | 0.031          | 0.13              | 0.02      | 0.21          |
| LDL-C/HDL-C ratio   | 0.03              | $< 0.01$       | 0.79             | 0.22           | 0.05          | 0.003          | -0.16             | 0.03      | 0.10          |
| Δ LDL-C/HDL-C ratio | -0.03             | $< 0.01$       | 0.76             | -0.23          | 0.05          | 0.002          | -0.24             | 0.06      | 0.02          |
| Triglyceride/HDL-C  | 0.18              | 0.03           | 0.07             | -0.08          | 0.01          | 0.41           | -0.02             | $< 0.01$ | 0.87          |
| Δ Triglyceride/HDL-C| 0.09              | 0.01           | 0.36             | -0.31          | 0.09          | 0.002          | -0.01             | $< 0.01$ | 0.87          |
| Non-HDL-C/HDL-C ratio | -0.01             | $< 0.01$       | 0.94             | 0.27           | 0.07          | 0.006          | 0.09              | 0.01      | 0.39          |
| Δ Non-HDL-C/HDL-C ratio | $< 0.01$         | $< 0.01$       | 0.94             | -0.27          | 0.07          | 0.007          | -0.09             | 0.01      | 0.38          |

Abbreviations: Apo B, apolipoprotein B; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; MDA-LDL, Malondialdehyde-modified low-density lipoprotein, Δ, each lipid profile value from the time of PCI to the follow-up CAG.